Core Viewpoint - The company reported a revenue increase of 8.49% in the first half of 2025, but continued to incur net losses, indicating ongoing financial challenges despite revenue growth [1][2]. Financial Performance - The company achieved operating revenue of 61.85 million yuan in the first half of 2025, compared to 57.01 million yuan in the same period last year, reflecting an increase of 8.49% [2]. - The net profit attributable to shareholders was -30.39 million yuan, worsening from -27.64 million yuan in the previous year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -30.43 million yuan, compared to -27.90 million yuan in the same period last year [2]. - The net cash flow from operating activities was -25.08 million yuan, a decline from -12.85 million yuan in the previous year [2]. Historical Financial Data - From 2021 to 2024, the company's operating revenues were 157 million yuan, 144 million yuan, 149 million yuan, and 153 million yuan respectively [2]. - The net profits attributable to shareholders for the same years were -45.61 million yuan, -79.10 million yuan, -67.93 million yuan, and -80.66 million yuan respectively [2]. - The net cash flow from operating activities for the years 2021 to 2024 was -65.07 million yuan, -56.57 million yuan, -29.88 million yuan, and -25.89 million yuan respectively [2]. Company Background - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 6, 2020, with an issuance of 18.4 million shares at a price of 28.21 yuan per share [3]. - The lead underwriter for the company's IPO was Zhongtai Securities Co., Ltd. [4]. - The highest stock price recorded after the IPO was 60.89 yuan on January 8, 2020 [5].